TherapeuticsMD (NASDAQ:TXMD) has been given a $9.00 target price by equities researchers at Deutsche Bank in a report released on Wednesday, December 20th. The brokerage presently has a “buy” rating on the stock. Deutsche Bank’s target price would indicate a potential upside of 44.23% from the company’s previous close.
Other research analysts also recently issued research reports about the stock. Oppenheimer reiterated an “outperform” rating and set a $10.00 price target on shares of TherapeuticsMD in a research report on Thursday, August 31st. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Morgan Stanley began coverage on shares of TherapeuticsMD in a research report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price target on the stock. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. TherapeuticsMD has a consensus rating of “Buy” and an average target price of $14.50.
Shares of TherapeuticsMD (TXMD) traded down $0.09 during trading hours on Wednesday, hitting $6.24. 1,784,086 shares of the stock traded hands, compared to its average volume of 2,670,000. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The firm has a market cap of $1,350.00, a P/E ratio of -16.00 and a beta of 1.06.
TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same quarter in the previous year, the company earned ($0.13) EPS. The firm’s revenue for the quarter was down 19.7% compared to the same quarter last year. analysts predict that TherapeuticsMD will post -0.37 EPS for the current year.
In related news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction dated Friday, December 8th. The stock was bought at an average cost of $6.21 per share, with a total value of $31,050.00. Following the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 23.92% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in TherapeuticsMD by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock worth $136,894,000 after purchasing an additional 2,985,846 shares in the last quarter. JPMorgan Chase & Co. increased its stake in TherapeuticsMD by 40.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after purchasing an additional 6,340,346 shares in the last quarter. Vanguard Group Inc. increased its stake in TherapeuticsMD by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after purchasing an additional 429,211 shares in the last quarter. State Street Corp increased its stake in TherapeuticsMD by 14.9% during the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after purchasing an additional 583,094 shares in the last quarter. Finally, Voya Investment Management LLC increased its stake in TherapeuticsMD by 33.4% during the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after purchasing an additional 741,588 shares in the last quarter. 73.69% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/therapeuticsmd-txmd-given-a-9-00-price-target-by-deutsche-bank-analysts.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.